Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy
Identifieur interne : 000117 ( Main/Exploration ); précédent : 000116; suivant : 000118Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy
Auteurs : RBID : ISTEX:259_1995_Article_BF01254561.pdfEnglish descriptors
- KwdEn :
Abstract
The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by isolated perfused rat livers and metabolism in vivo in normal and tumour-bearing rats were determined and compared to those of indium-111 DTPA-octreotide. The results of the binding studies demonstrate that161Tb-DTPA-octreotide is a high-affinity radioligand for somatostatin receptors, with an affinity comparable to that of111In-DTPA-octreotide. Rat growth hormone secretion inhibition experiments showed that161Tb-DTPA-octreotide has a similar potency to111In-DTPA-octreotide.161Tb-DTPA-octreotide appeared to be taken up even less by the isolated perfused rat liver than111In-DTPA-octreotide, as almost no tracer disappeared from the perfusion medium. Furthermore, hardly any radioactivity was found in the liver, and excretion into the bile was negligible. The biodistribution studies showed that for octreotide receptor-positive organs, such as pancreas and adrenals, uptake of161Tb-DTPA-octreotide is lower then that of111In-DTPA-octreotide. However, as the clearance from the blood of the former compound is faster than that of the latter, the tissue/blood ratio is higher in the case of161Tb-DTPA-octreotide than with111In-DTPA-octreotide. Furthermore, these studies demonstrated that the uptake of161Tb-DTPA-octreotide by the renal tubular cells after glomerular filtration can be reduced by administration of lysine or sodium maleate. Increase in urine production before and during the experiment had no effect on the kidney uptake of161Tb-DTPA-octreotide. Finally, it appeared that a maximal labelling efficiency of161Tb-DTPA-octreotide is essential, as with decreasing efficiency the uptake in the octreotide receptor-positive organs decreased, whereas non-specific uptake in the other organs was increased. It is concluded that, on the basis of the favourable physical characteristics of161Tb combined with the in vitro and in vivo studies performed with161Tb-DTPA-octreotide, the latter is a promising radiopharmaceutical for both intraoperative scanning and radiotherapy. Studies in patients need to be performed now to see whether161Tb-DTPA-octreotide can indeed open new therapeutic applications for patients bearing octreotide receptor-positive tumours.
DOI: 10.1007/BF01254561
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy</title>
<author><name>Marion de Jong</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam</wicri:regionArea>
<wicri:noRegion>GD Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Wout A. P. Breeman</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam</wicri:regionArea>
<wicri:noRegion>GD Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Bert F. Bernard</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Edgar J. Rolleman</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam</wicri:regionArea>
<wicri:noRegion>GD Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Leo J. Hoflande</name>
<affiliation wicri:level="1"><mods:affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Dr. Daniël den Hoed Cancer Centre, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Theo J. Visser</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Buddy Setyono-Han</name>
<affiliation wicri:level="1"><mods:affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Dr. Daniël den Hoed Cancer Centre, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Willem H. Bakker</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam</wicri:regionArea>
<wicri:noRegion>GD Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Marcel E. van der Pluijm</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam</wicri:regionArea>
<wicri:noRegion>GD Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author><name>Eric P. Krenning</name>
</author>
</titleStmt>
<publicationStmt><idno type="RBID">ISTEX:259_1995_Article_BF01254561.pdf</idno>
<date when="1995">1995</date>
<idno type="doi">10.1007/BF01254561</idno>
<idno type="wicri:Area/Main/Corpus">000674</idno>
<idno type="wicri:Area/Main/Curation">000674</idno>
<idno type="wicri:Area/Main/Exploration">000117</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>In vivo distribution</term>
<term>Liver perfusion</term>
<term>Rats</term>
<term>Receptors binding</term>
<term>Terbium-161 diethylene triamine penta-acetic acid labelled octreotide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by isolated perfused rat livers and metabolism in vivo in normal and tumour-bearing rats were determined and compared to those of indium-111 DTPA-octreotide. The results of the binding studies demonstrate that161Tb-DTPA-octreotide is a high-affinity radioligand for somatostatin receptors, with an affinity comparable to that of111In-DTPA-octreotide. Rat growth hormone secretion inhibition experiments showed that161Tb-DTPA-octreotide has a similar potency to111In-DTPA-octreotide.161Tb-DTPA-octreotide appeared to be taken up even less by the isolated perfused rat liver than111In-DTPA-octreotide, as almost no tracer disappeared from the perfusion medium. Furthermore, hardly any radioactivity was found in the liver, and excretion into the bile was negligible. The biodistribution studies showed that for octreotide receptor-positive organs, such as pancreas and adrenals, uptake of161Tb-DTPA-octreotide is lower then that of111In-DTPA-octreotide. However, as the clearance from the blood of the former compound is faster than that of the latter, the tissue/blood ratio is higher in the case of161Tb-DTPA-octreotide than with111In-DTPA-octreotide. Furthermore, these studies demonstrated that the uptake of161Tb-DTPA-octreotide by the renal tubular cells after glomerular filtration can be reduced by administration of lysine or sodium maleate. Increase in urine production before and during the experiment had no effect on the kidney uptake of161Tb-DTPA-octreotide. Finally, it appeared that a maximal labelling efficiency of161Tb-DTPA-octreotide is essential, as with decreasing efficiency the uptake in the octreotide receptor-positive organs decreased, whereas non-specific uptake in the other organs was increased. It is concluded that, on the basis of the favourable physical characteristics of161Tb combined with the in vitro and in vivo studies performed with161Tb-DTPA-octreotide, the latter is a promising radiopharmaceutical for both intraoperative scanning and radiotherapy. Studies in patients need to be performed now to see whether161Tb-DTPA-octreotide can indeed open new therapeutic applications for patients bearing octreotide receptor-positive tumours.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="73cfae7416034728cc7c73de4c331a18d1b8177a"><titleInfo lang="eng"><title>Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy</title>
</titleInfo>
<name type="personal"><namePart type="given">Marion</namePart>
<namePart type="family">de Jong</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Wout A. P.</namePart>
<namePart type="family">Breeman</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Bert F.</namePart>
<namePart type="family">Bernard</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Edgar J.</namePart>
<namePart type="family">Rolleman</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Leo J.</namePart>
<namePart type="family">Hoflande</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Theo J.</namePart>
<namePart type="family">Visser</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Internal Medicine III, Erasmus Medical School and University Hospital Rotterdam, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Buddy</namePart>
<namePart type="family">Setyono-Han</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Willem H.</namePart>
<namePart type="family">Bakker</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Marcel E.</namePart>
<namePart type="family">van der Pluijm</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Rotterdam, 3015, GD Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal"><namePart type="given">Eric P.</namePart>
<namePart type="family">Krenning</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1994-10-05</dateCreated>
<dateValid encoding="w3cdtf">2005-02-18</dateValid>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by isolated perfused rat livers and metabolism in vivo in normal and tumour-bearing rats were determined and compared to those of indium-111 DTPA-octreotide. The results of the binding studies demonstrate that161Tb-DTPA-octreotide is a high-affinity radioligand for somatostatin receptors, with an affinity comparable to that of111In-DTPA-octreotide. Rat growth hormone secretion inhibition experiments showed that161Tb-DTPA-octreotide has a similar potency to111In-DTPA-octreotide.161Tb-DTPA-octreotide appeared to be taken up even less by the isolated perfused rat liver than111In-DTPA-octreotide, as almost no tracer disappeared from the perfusion medium. Furthermore, hardly any radioactivity was found in the liver, and excretion into the bile was negligible. The biodistribution studies showed that for octreotide receptor-positive organs, such as pancreas and adrenals, uptake of161Tb-DTPA-octreotide is lower then that of111In-DTPA-octreotide. However, as the clearance from the blood of the former compound is faster than that of the latter, the tissue/blood ratio is higher in the case of161Tb-DTPA-octreotide than with111In-DTPA-octreotide. Furthermore, these studies demonstrated that the uptake of161Tb-DTPA-octreotide by the renal tubular cells after glomerular filtration can be reduced by administration of lysine or sodium maleate. Increase in urine production before and during the experiment had no effect on the kidney uptake of161Tb-DTPA-octreotide. Finally, it appeared that a maximal labelling efficiency of161Tb-DTPA-octreotide is essential, as with decreasing efficiency the uptake in the octreotide receptor-positive organs decreased, whereas non-specific uptake in the other organs was increased. It is concluded that, on the basis of the favourable physical characteristics of161Tb combined with the in vitro and in vivo studies performed with161Tb-DTPA-octreotide, the latter is a promising radiopharmaceutical for both intraoperative scanning and radiotherapy. Studies in patients need to be performed now to see whether161Tb-DTPA-octreotide can indeed open new therapeutic applications for patients bearing octreotide receptor-positive tumours.</abstract>
<subject lang="eng"><genre>Key words</genre>
<topic>Terbium-161 diethylene triamine penta-acetic acid labelled octreotide</topic>
<topic>Rats</topic>
<topic>Receptors binding</topic>
<topic>Liver perfusion</topic>
<topic>In vivo distribution</topic>
</subject>
<relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo><title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1995</partNumber>
<partNumber>Volume: 22</partNumber>
<partNumber>Number: 7</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1995-07-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<subject usage="primary"><topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 19</identifier>
<recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF01254561</identifier>
<identifier type="matrixNumber">Art3</identifier>
<identifier type="local">BF01254561</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part><extent unit="pages"><start>608</start>
<end>616</end>
</extent>
</part>
<recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin>
<recordIdentifier>259_1995_Article_BF01254561.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= IndiumV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:259_1995_Article_BF01254561.pdf |texte= Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy }}
This area was generated with Dilib version V0.5.81. |